Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. 2010

Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
Center of Drug Discovery, China Pharmaceutical University, 210009 Nanjing, PR China.

A set of amide- and amine-linked hybrid molecules comprising moieties of the orthosteric M(1) muscarinic receptor agonist xanomeline and the cholinesterase inhibitor and allosteric receptor modulator tacrine were prepared with varying spacer length of 10-17 atoms. The hybrids inhibited acetylcholinesterase with similar or higher potency compared to tacrine. M(1) receptor binding affinity was similar or higher relative to xanomeline and far higher relative to tacrine. Affinities hardly changed when the receptors' orthosteric site was occupied by an inverse agonist ligand. When occupied by the orthosteric activator acetylcholine, affinity for the hybrids declined to unmeasureably low levels. Hybrids did not activate M(1) receptors. In vivo studies assaying cognition impairment in rats induced by scopolamine revealed pronounced enhancement of scopolamine action. Taken together, instead of dualsteric (simultaneous allosteric/orthosteric) binding, the hybrids seem to prefer purely allosteric binding at the inactive M(1) receptor.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002491 Central Nervous System Agents A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252) Central Nervous System Drugs
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D002802 Cholinesterases Acylcholineacylhydrolase,Cholase,Cholinesterase
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D005260 Female Females
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
March 2020, Bioorganic chemistry,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
September 1997, European journal of pharmacology,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
April 1994, The Journal of pharmacology and experimental therapeutics,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
November 2007, Journal of medicinal chemistry,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
January 2004, The Journal of pharmacology and experimental therapeutics,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
January 1995, Life sciences,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
April 1994, The Journal of pharmacology and experimental therapeutics,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
June 2017, MedChemComm,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
June 1998, Molecular pharmacology,
Lei Fang, and Sabine Jumpertz, and Yihua Zhang, and Dorothea Appenroth, and Christian Fleck, and Klaus Mohr, and Christian Tränkle, and Michael Decker
February 2022, Scientific reports,
Copied contents to your clipboard!